Kyntra Bio, Inc. Common Stock (KYNB) is a publicly traded the market company. As of May 21, 2026, KYNB trades at $6.95 with a market cap of $27.65M and a P/E ratio of 0.00. KYNB moved +0.00% today. Year to date, KYNB is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $6.32 to $9.70. Analyst consensus is buy with an average price target of $43.00. Rallies surfaces KYNB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Kyntra Bio Posts Q1 $3.7M Revenue, $100M Cash Runway; FG-3246 Interim Analysis Slated Q4 2026: Kyntra Bio reported Q1 revenue of $3.7m, reduced net loss to $15.1m, and held $100.3m in cash, funding operations into 2028. The Phase 2 trial of FG-3246 in mCRPC is on track for a Q4 2026 interim analysis, and its Phase 3 roxadustat protocol is finalizing for H2 2026 start.
| Metric | Value |
|---|---|
| Price | $6.95 |
| Market Cap | $27.65M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.70 |
| 52-Week Low | $6.32 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
2 analysts cover KYNB: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $43.00.